Ozagrel sodium
[CAS# 189224-26-8]

Identification

• Classification: API >> Blood system medication >> Anticoagulant and antiplatelet drugs
• Name: Ozagrel sodium
• Synonyms: (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic acid sodium salt
• Molecular Formula: C₁₃H₁₁N₂NaO₂
• Molecular Weight: 250.23
• CAS Registry Number: 189224-26-8 (130952-46-4)
• EC Number: 988-659-9
• SMILES: C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)[O-].[Na+]

Properties

• Solubility: 10 mM (DMSO) (Expl.)

Safety Data

• Hazard Symbols: GHS08 Warning
• Risk Statements: H371
• Safety Statements: P260-P264-P270-P308+P316-P405-P501

Discovery and Applications

Ozagrel sodium is a pharmacologically active compound classified as a thromboxane A₂ synthase inhibitor. It is primarily used in clinical settings to inhibit platelet aggregation and promote vasodilation by selectively blocking the synthesis of thromboxane A₂, a potent vasoconstrictor and promoter of platelet aggregation. This mechanism makes ozagrel sodium useful in the treatment and prevention of conditions associated with thrombosis and ischemia, such as cerebral infarction and other vascular disorders.

Ozagrel was first synthesized in the 1980s during research aimed at developing selective inhibitors of thromboxane synthase, with the goal of providing targeted antiplatelet effects while minimizing side effects commonly associated with non-selective cyclooxygenase inhibitors. The sodium salt form improves the compound’s solubility and stability, facilitating its administration in clinical formulations.

The primary therapeutic application of ozagrel sodium has been in the management of cerebrovascular diseases, particularly ischemic stroke. By inhibiting thromboxane A₂ synthesis, ozagrel reduces platelet aggregation and vasoconstriction, improving cerebral blood flow and reducing the risk of thrombus formation. This pharmacological effect contributes to limiting the extent of ischemic injury and improving patient outcomes. Ozagrel has been used both in acute treatment settings and as part of secondary prevention strategies in patients at risk of recurrent stroke.

Ozagrel sodium has also been explored for its potential benefits in other vascular conditions where thromboxane A₂ plays a pathological role, such as peripheral arterial disease and certain cardiovascular diseases. Its vasodilatory properties and antiplatelet activity have made it a subject of investigation for improving microcirculatory function and reducing vascular complications.

Pharmacokinetically, ozagrel sodium is administered orally or intravenously depending on the clinical context. It is absorbed and distributed systemically, with metabolic processing primarily in the liver. The elimination half-life allows for dosing regimens that maintain effective thromboxane synthase inhibition over a therapeutic period.

Safety and tolerability data from clinical studies indicate that ozagrel sodium is generally well tolerated when used at recommended doses. Side effects may include mild gastrointestinal symptoms, such as nausea or abdominal discomfort, and less commonly, bleeding tendencies due to its antiplatelet effect. Monitoring is recommended when used concomitantly with other anticoagulant or antiplatelet therapies to mitigate the risk of bleeding complications.

In summary, ozagrel sodium is a selective thromboxane A₂ synthase inhibitor used primarily to prevent and treat thrombotic and ischemic vascular conditions, especially ischemic stroke. Its mechanism of reducing platelet aggregation and vasoconstriction supports its therapeutic role in improving vascular blood flow and reducing thrombotic risk. The drug’s development and clinical use have contributed to expanded options for targeted antiplatelet therapy.

References

2019. Ozagrel for Postoperative Management of Aneurysmal Subarachnoid Hemorrhages. Neurology India, 67(5).
DOI: 10.4103/0028-3886.271236

2021. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundamental & Clinical Pharmacology, 35(3).
DOI: 10.1111/fcp.12610

2022. Photoisomerization of Sulindac and Ozagrel Hydrochloride by Vitamin B2 Catalyst Under Visible Light Irradiation. Pharmaceutical Research, 39(3).
DOI: 10.1007/s11095-022-03203-3